To summarize the mechanisms by which hepatic lipid metabolic dysregulation drives metabolic dysfunction-associated fatty liver disease (MAFLD) progression and highlight recent advances in therapeutic strategies targeting these pathways.
Key Findings:
MAFLD is linked to metabolic dysfunctions like obesity and type 2 diabetes.
Disruption of hepatic lipid metabolism is a central event in MAFLD progression.
Specific lipid metabolites act as signaling molecules influencing insulin resistance and inflammation, highlighting the complexity of their interactions.
Dysregulation of a network of lipid metabolism, rather than isolated pathways, drives MAFLD.
Interpretation:
The findings suggest a paradigm shift in understanding MAFLD, emphasizing the need for multi-target interventions that address the complex interactions of lipid species and their implications for treatment strategies.
Limitations:
The precise pathogenic mechanisms of MAFLD remain incompletely understood.
Effective pharmacological treatments are still lacking.
More clinical trials are needed to validate the proposed therapeutic strategies.
Conclusion:
Targeting toxic lipid species while preserving physiological lipid functions offers promising directions for MAFLD drug development.
